News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NuVasive, Inc. (NUVA) Names Carol Cox Executive Vice President Strategy And Corporate Communications



7/7/2014 11:08:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, CA--(Marketwired - July 07, 2014) - NuVasive, Inc. (NASDAQ: NUVA), announced today that Carol Cox has joined the company as executive vice president of Strategy and Corporate Communications effective immediately. She will report directly to Alex Lukianov, Chairman and Chief Executive Officer of NuVasive, and will join the company's Executive Committee.

In this newly created role, Cox will be responsible for leading NuVasive's short- and long-term business strategies, as well as creating and managing a centralized communications function to ensure global alignment of messaging and leveraging of assets across the key areas of corporate communications, investor relations and public affairs. Included in Cox's responsibilities will also be overseeing NuVasive corporate philanthropic and cultural efforts.

"As we continue to invest in initiatives to grow NuVasive's share of the global spine market and focus on improving our profitability, communicating our business strategy to our stakeholders and integrating our communications efforts has never been more important," said Alex Lukianov, Chairman and CEO of NuVasive. "Carol's broad range of experience in positioning companies in the pharmaceutical, medical devices and life-science industries, as well as her knowledge of global business and markets, makes her an ideal leader to spearhead our strategic communications. She is a strong addition to our leadership team."

"I am pleased to join Alex and the team at NuVasive as we build upon and execute against the strategies that will support our continued growth in the minimally disruptive spine market, expand our global footprint and integrate our communications efforts to help drive sustainable value for our customers, stockholders and internal employee shareowners," said Ms. Cox.

Cox is an executive with extensive global healthcare experience in corporate strategy, investor relations, corporate communications, media relations, brand strategy and government relations. She joins NuVasive from Sanford-Burnham Medical Research Institute (Sanford-Burnham) where she served as senior vice president, External Affairs, leading external and internal communications, philanthropy, marketing, government relations and efforts to elevate the Institute's global recognition. Prior to Sanford- Burnham, she served as senior vice president of External Affairs and Corporate Communications at Life Technologies, where she spearheaded global strategies to drive awareness of the company's major initiatives, enhance its global brand, and maintain its corporate reputation across multiple stakeholder groups. Before joining Life Technologies, Cox was vice president of Investor Relations at CareFusion Corporation and senior vice president for Global Corporate Communications and Investor Relations at Barr Pharmaceuticals. She holds a bachelor's of arts degree in Foreign Affairs from the University of Virginia and a certificate in Investor Relations from The University of Connecticut School of Business.

About NuVasive
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.7 billion global spine market.

NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game-changing technology such as the XLIF Decade™ plate for single-approach fixation through a lateral incision, the PCM® motion-preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and the Armada® posterior fixation system, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedurally integrated solutions that completely redefine and improve upon traditional techniques like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation, and Absolute Responsiveness®.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, our ability to effectually manage inventory as we continue to release new products, and the other risks and uncertainties described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Investor Contact:
Tina Jacobsen
NuVasive, Inc.
858-320-5215 investorrelations@nuvasive.com

Media Contact:
Margie Elsesser
NuVasive, Inc.
858-437-1125
media@nuvasive.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES